clinical trial · NCT05024994
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic LeukemiaE7820
brief summary
The researchers are doing this study to find out whether E7820 is an effective treatment for people with relapsed/refractory myeloid cancers with mutations in splicing factor genes. Participants will have acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML).
started
Aug 13, 2021
primary completion
Jun 19, 2025
completion
Jun 19, 2025
last updated
Jun 17, 2026
official title
A Phase II Clinical Trial of E7820 for Patients With Relapsed/Refractory Myeloid Malignancies With Mutations in Splicing Factor Genes.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol